In 2009, the recommendations of the Czech Collaborative Group for Ph- myeloproliferative diseases (CZEMP) for diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases (MPD), i.e. essential thrombocythemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF) were updated und extended. The present article gives the rationale of the recommendations in full detail.
The CZEMP diagnostic criteria for ET and PMF are based on histopathological (HP) findings, which must unconditionally be in line with the given clinical and laboratory characteristics of ET or of certain stage of PMF, respectively.